PLAINSBORO, N.J., June 2, 2020 /PRNewswire/ -- Novo Nordisk
announced that new data from 38 abstracts will be featured from the
company's approved and investigational diabetes medicines at the
upcoming 80th Annual Scientific Sessions of the
American Diabetes Association (ADA). The meeting will be held
virtually from June 12-16, 2020. The
company is proud to continue its innovation in diabetes treatment
with Rybelsus® (semaglutide) tablets 7 mg or 14 mg,
as well as a phase 2 clinical trial of investigational, once-weekly
insulin icodec.
Approved by the U.S. Food and Drug Administration in
September 2019, Rybelsus®
is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist
indicated as an adjunct to diet and exercise to improve glycemic
control in adults with type 2 diabetes mellitus. The following data
on Rybelsus® will be presented during the meeting:
- Glycemic and body weight responses to oral semaglutide in the
PIONEER trial program (Poster 964-P)
- Effect of oral semaglutide with or without background SGLT2i in
patients with T2D: subgroup analysis of PIONEER 4 (Poster
927-P)
- Efficacy and safety of oral semaglutide when added to basal,
premix, or basal-bolus insulin (Poster 956-P)
- Efficacy of oral semaglutide according to background
medication: an exploratory subgroup analysis of the PIONEER trial
program (Poster 957-P)
- Efficacy of oral semaglutide according to race: an exploratory
subgroup analysis of the PIONEER trial program (Poster 930-P)
- Efficacy and safety of oral semaglutide by baseline age in the
PIONEER clinical trial program (Poster 932-P)
- Cost Effectiveness of Oral Semaglutide 14 mg vs Empagliflozin
25 mg in Canada (Poster
1193-P)
Results from a phase 2 clinical trial of investigational insulin
icodec will be presented on June 14. Insulin icodec is an
investigational, once-weekly basal insulin analogue. The following
data will be presented during the meeting:
- Once-weekly basal insulin icodec efficacy and safety vs
once-daily insulin glargine U100 in insulin naïve patients with T2D
(Oral 238-OR)
- Molecular and biological properties of insulin icodec, an
investigational insulin analog designed to have a long half-life
suitable for once weekly dosing (Oral 236-OR)
- Insulin icodec: an investigational insulin analog designed for
once-weekly dosing in type 2 diabetes (Oral 237-OR)
In addition, the following data will also be presented at the
meeting:
- HbA1c levels and rates of hypoglycemia with insulin degludec
U200 and insulin glargine U300 stratified by renal function
subgroups: post hoc analysis from the CONCLUDE trial (Poster
1021-P)
- Derived time-in-range and associated risk of MACE in T2D: data
from the DEVOTE trial (Poster 21-LB)
- Efficacy and safety of anti-interleukin (IL)-21 in combination
with liraglutide in adults recently diagnosed with type 1 diabetes
(Oral 278-OR)
- GLP-1-experienced patients switching to once-weekly semaglutide
in a real-world setting (EXPERT study) (Poster 954-P)
- Optimal treatment intensification for glycemic control in
patients with T2D on two oral agents: real world comparison of
GLP-1, OADs and insulin (Poster 931-P)
- Effect of late bolus injections on Time-in-Range studied by
connected pens (Poster 975-P)
The above abstracts and presentations are a sampling of the data
that will be presented or published by Novo Nordisk. This press
release contains forward-looking statements about investigational
products currently in development by Novo Nordisk. As is expected,
there is significant risk with drug development and there is no
guarantee that future studies will reflect similar results as
presented at ADA. For further information about the Novo Nordisk
drug pipeline, visit http://www.novonordisk.us.
About
Rybelsus®
Rybelsus® (semaglutide)
tablets 7 mg or 14 mg is an analog of the naturally occurring
hormone GLP-1. Rybelsus® is the first and only GLP-1
receptor agonist in a pill. It is administered once daily and is
approved for use in two therapeutic doses: 7 mg and 14 mg.
About insulin icodec
Insulin icodec is an
investigational, long-acting basal insulin analogue with a
half-life of ~196 hours.1 Once injected, insulin icodec
binds strongly but reversibly to albumin. This results in a
continuous slow and steady reduction of blood sugar over the week.
The volume of insulin required to be injected does not increase
with once-weekly dosing, as insulin icodec is more concentrated
than insulin glargine U100.
About Novo Nordisk
Novo Nordisk is a
global healthcare company that's been making innovative medicines
to help people with diabetes lead longer, healthier lives for 95
years. This heritage has given us experience and capabilities that
also enable us to help people defeat other serious diseases
including obesity, hemophilia and growth disorders. We remain
steadfast in our conviction that the formula for lasting success is
to stay focused, think long-term and do business in a financially,
socially and environmentally responsible way. With U.S.
headquarters in New Jersey and
production and research facilities in six states, Novo Nordisk
employs nearly 6,000 people throughout the country. For more
information, visit novonordisk.us, Facebook, Instagram and
Twitter.
References
- Hövelmann U, Brøndsted L, Kristensen NR, et al. Insulin
Icodec: An Insulin Analog Suited For Once-weekly Dosing In Type 2
Diabetes. Presented at the 80th Scientific Sessions of the Virtual
American Diabetes Association Annual Meeting. 2020.
Rybelsus® is a registered trademark of Novo Nordisk
A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2020 Novo Nordisk All rights
reserved.
US20RYB00386 June
2020
View original
content:http://www.prnewswire.com/news-releases/novo-nordisk-to-present-new-data-at-the-80th-annual-american-diabetes-association-scientific-sessions-301068837.html
SOURCE Novo Nordisk